Cognition Therapeutics Q1 net loss $9.2M; cash runway through Q2 2025; SHINE data mid-2024

COGNITION THERAPEUTICS INC

2024-Q1 EPS reported -$0.27

Net loss of $9.2M ($0.27/share) vs $6.2M ($0.21/share) in Q1 2023.
Cash and equivalents $34.7M plus $62.3M in NIA grant funds; sufficient through Q2 2025.
R&D expenses rose to $10.6M from $5.4M, driven by Phase 2 trial activities.
Topline SHINE (Alzheimer's) results expected mid-2024; SHIMMER (DLB) enrolled 130 participants.
Completed follow-on offering in March 2024, netting $11.9M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.

Period: first quarter ended March 31, 2024
Net income: $9.2 million
EPS: $(0.27) per basic and diluted share
Result: reported results

Exact text from the filing

The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-24-057711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.